证券代码：002513 证券简称：蓝丰生化 公告编号：2024-043 江苏蓝丰生物化工股份有限公司 第七届董事会第十一次会议决议公告 表决结果：8 票同意，0 票反对，0 票弃权。 具体详见 2024 年 5 月 21 日刊登在公司指定信息披露网站巨潮资讯网 （www.cninfo.com.cn）及《上海证券报》、《证券时报》、《中国证券报》上的 相关公告。 三、备查文件 1、公司第七届董事会第十三次会议决议。 本公司及董事会全体成员保证公告内容真实、准确和完整，不存在虚假记载、 误导性陈述或者重大遗漏。 一、董事会会议召开情况 江苏蓝丰生物化工股份有限公司（以下简称"公司"）第七届董事会第十三 次会议于 2024 年 5 月 20 日以通讯表决方式召开。本次会议已于 2024 年 5 月 17 日以微信、电子邮件的方式通知全体董事。本次会议由公司董事长郑旭先生主持， 会议应出席董事 8 人，实际出席董事 8 人，监事和高管列席会议。本次会议的召 集、召开及表决程序符合《公司法》和《公司章程》的规定，合法有效。 二、董事会会议审议情况 （一）审议通过《关于控股二级子公司对外投资的议案》 公司控股二级子公司安 ...

证券代码：002513 证券简称：蓝丰生化 公告编号：2024-042 江苏蓝丰生物化工股份有限公司 关于子公司对外投资的公告 本公司及董事会全体成员保证公告内容的真实、准确、完整，没有虚假记载、 误导性陈述或者重大遗漏。 一、对外投资概述 江苏蓝丰生物化工股份有限公司（以下简称"公司"）于 2024 年 5 月 20 日 召开了第七届董事会第十三次会议，审议通过了《关于控股二级子公司对外投资 的议案》。公司控股二级子公司安徽旭合清洁能源科技有限公司（以下简称"旭 合清能"）拟与广西博堃能源科技有限公司（以下简称"广西博堃"）共同投资， 在安徽设立安徽旭博新能源科技有限公司（暂定名，以下简称"安徽旭博"或"合 资公司"），以合资公司为平台，开展分布式光伏电站开发等业务。合资公司注 册资本为 500 万元人民币，其中，旭合清能以自有资金出资 255 万元人民币，占 合资公司注册资本的 51%；广西博堃以自有资金出资 245 万元人民币，占合资公 司注册资本的 49%。 根据《深圳证券交易所股票上市规则》以及《公司章程》的相关规定，本次 对外投资事项在公司董事会审议权限内，无需提交公司股东大会审议批准。 本次对外 ...

证券代码：002513 证券简称：蓝丰生化 江苏蓝丰生物化工股份有限公司 投资者关系活动记录表 编号：2024-001 投资者关系活动类别 ☐特定对象调研 ☐分析师会议 ☐媒体采访 业绩说明会 ☐新闻发布会 ☐路演活动 ☐现场参观 ☐其他（请文字说明其他活动内容） 线上参与公司2023年度网上业绩说明会的全体投资者 参与单位名称及人员姓名 2024年05月16日 15:00-17:00 时间 价值在线（https://www.ir-online.cn/）网络互动 地点 董事长 郑旭 董事、总经理 李质磊 副总经理、财务总监 邢军 上市公司接待人员姓名 副总经理、董事会秘书 唐海军 独立董事 袁坚 ...

会议召开地点：价值在线（www.ir-online.cn） 会议召开方式：网络互动方式 证券代码：002513 证券简称：蓝丰生化 公告编号：2024-041 江苏蓝丰生物化工股份有限公司 关于举办 2023 年度网上业绩说明会的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，不存在虚假记载、 误导性陈述或者重大遗漏。 江苏蓝丰生物化工股份有限公司（以下简称"公司"）已于 2024 年 4 月 30 日在巨潮资讯网（http://www.cninfo.com.cn/）上披露了公司《2023 年年度报 告》及《2023 年年度报告摘要》。 为便于广大投资者更加全面深入地了解公司经营业绩、发展战略等情况，公 司定于 2024 年 5 月 16 日（星期四）15:00-17:00 在"价值在线"（www.ir- online.cn）举办江苏蓝丰生物化工股份有限公司 2023 年度网上业绩说明会，与 投资者进行沟通和交流，广泛听取投资者的意见和建议。 一、说明会召开的时间、地点和方式 会议召开时间：2024年5月16日（星期四）15:00-17:00 2024 年 5 月 9 日 2 二、参加人员 参加本次 ...

关于控股子公司获得政府补助的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 证券代码：002513 证券简称：蓝丰生化 公告编号：2024-040 江苏蓝丰生物化工股份有限公司 1 本次收到的政府补助款预计对控股子公司现金流产生积极影响。旭合科技收 到的计入递延收益的政府补助将在相关资产使用寿命内分期计入损益（根据公司 会计政策，旭合科技主要机器设备的使用期为 10 年）。 4、风险提示和其他说明 一、 获得政府补助的基本情况 近日，根据江苏蓝丰生物化工股份有限公司（以下简称"公司"）的控股子公 司安徽旭合新能源科技有限公司（以下简称"旭合科技"）与中新苏滁高新技术 产业开发区管理委员会、中新苏滁（滁州）开发有限公司签订的《"10GW 超高效 N 型光伏电池及组件"项目补充协议书》相关条款，旭合科技收到滁州市中新苏 滁建设发展集团有限公司（注：中新苏滁高新技术产业开发区土地储备中心、滁 州市人民政府国有资产监督管理委员会合计持有其 100%股权）下发的固定资产 投资补助款人民币 3,000 万元，占上市公司最近一期经审计净资产 118.95%，上 述补贴 ...

截至本公告披露日，刘安平先生因公司 2021 年限制性股票激励计划持有公 司股票 340 万股，其中已获授但解除限售条件未达成需要回购注销的限制性股票 204 万股。刘安平先生辞职后，其所持股份将严格按照《深圳证券交易所上市公 司自律监管指引第 1 号—主板上市公司规范运作》《深圳证券交易所上市公司自 律监管指引第 10 号—股份变动管理》《上市公司股东、董监高减持股份的若干 规定》《深圳证券交易所上市公司股东及董事、监事、高级管理人员减持股份实 施细则》等相关法律法规及《江苏蓝丰生物化工股份有限公司 2021 年限制性股 票激励计划（草案）》的相关规定进行管理。 刘安平先生在担任公司副总经理期间，勤勉尽责、恪尽职守，公司及董事会 对刘安平先生任职期间为公司发展所付出的努力表示衷心感谢！ 特此公告。 江苏蓝丰生物化工股份有限公司董事会 本公司及董事会全体成员保证公告内容真实、准确和完整，不存在虚假记载、 误导性陈述或者重大遗漏。 江苏蓝丰生物化工股份有限公司（以下简称"公司"）董事会于近日收到公 司副总经理刘安平先生递交的书面辞职报告。刘安平先生因工作调整申请辞去公 司副总经理职务，辞去上述职务后，刘安平先生 ...

证券代码：002513 证券简称：蓝丰生化 公告编号：2024-039 江苏蓝丰生物化工股份有限公司 关于公司涉及诉讼的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，不存在虚假记载、 误导性陈述或者重大遗漏。 特别提示： 1、案件所处的诉讼阶段：法院已受理，尚未开庭 一、本次诉讼事项受理的基本情况 江苏蓝丰生物化工股份有限公司（以下简称"公司"或"蓝丰生化"）于近 日收到江西省玉山县人民法院送达的案号为(2024)赣 1123 民初 1474 号及案号 为(2024)赣 1123 民初 1372 号《传票》和《民事起诉状》等相关法律文书，现将 有关情况公告如下： 二、有关案件的基本情况 （一）玉山工投、玉山创新诉江西德施普、蓝丰生化、刘智买卖合同纠纷 案 1 1、诉讼各方当事人名称 原告一：玉山县工投供应链管理有限公司（以下简称"玉山工投"） 原告二：玉山县创新发展贸易有限公司（以下简称"玉山创新"） 被告一：江西德施普新材料有限公司 2、上市公司所处的当事人地位：被告 3、涉案金额：19,461,464.72 元 4、对公司损益产生的影响：本次诉讼尚未开庭审理，对本期利润及期后利 润的影响尚不确 ...

Financial Performance - The company's revenue for Q1 2024 was ¥378,109,304.42, a decrease of 0.94% compared to ¥381,711,743.06 in the same period last year[5] - The net loss attributable to shareholders was ¥30,509,968.18, representing a 107.17% increase in losses from ¥14,727,136.62 in the previous year[5] - Total operating revenue for Q1 2024 was CNY 378.11 million, a decrease of 0.42% compared to CNY 381.71 million in the same period last year[16] - Net loss for Q1 2024 was CNY 42.48 million, compared to a net loss of CNY 14.81 million in Q1 2023, representing a significant increase in losses[17] - The basic and diluted earnings per share for Q1 2024 were both negative CNY 0.0825, compared to negative CNY 0.0433 in Q1 2023[18] Cash Flow - The net cash flow from operating activities was -¥98,675,401.02, a decline of 194.98% compared to -¥33,451,158.01 in the same period last year[5] - Cash flow from operating activities showed a net outflow of CNY 98.68 million, worsening from a net outflow of CNY 33.45 million in the same quarter last year[19] - The net cash flow from investment activities was -15,039,484.92 CNY, compared to -818,889.30 CNY in the previous year[20] - Cash inflow from financing activities totaled 205,136,621.05 CNY, up from 105,030,100.00 CNY year-over-year[20] - The net cash flow from financing activities was 131,847,903.81 CNY, significantly higher than 34,357,842.57 CNY in the same period last year[20] - The cash and cash equivalents at the end of the period increased to 35,217,795.77 CNY from 8,906,465.49 CNY year-over-year[20] Assets and Liabilities - The company's total assets decreased by 3.41% to ¥3,283,814,284.87 from ¥3,399,589,930.03 at the end of the previous year[5] - Total current assets decreased from CNY 1,575,672,725.35 to CNY 1,462,962,235.41, a decline of approximately 7.14%[12] - Total non-current assets slightly decreased from CNY 1,823,917,204.68 to CNY 1,820,852,049.46, a marginal decline of about 0.17%[13] - The company reported a total liability of CNY 3.07 billion, a decrease from CNY 3.15 billion in the previous quarter[17] - Total current liabilities decreased from CNY 2,517,475,798.31 to CNY 2,410,380,085.10, a reduction of about 4.24%[13] Shareholder Information - Total number of common shareholders at the end of the reporting period is 15,336[10] - The largest shareholder, Zheng Xu, holds 18.04% of shares, totaling 67,457,432 shares, with 33,500,000 shares pledged[10] Inventory and Receivables - Accounts receivable decreased by 28.12% to ¥261,193,454.89, primarily due to an increase in cash collections[8] - Inventory increased by 68.40% to ¥282,520,812.57, mainly due to an increase in raw material stockpiling[8] - Accounts receivable decreased from CNY 363,357,301.83 to CNY 261,193,454.89, a reduction of about 28.14%[12] - Inventory increased significantly from CNY 167,768,426.09 to CNY 282,520,812.57, an increase of approximately 68.25%[12] Research and Development - Research and development expenses surged by 923.42% to ¥27,074,326.90, reflecting increased investment in R&D activities[8] - Research and development expenses surged to CNY 27.07 million, a substantial increase from CNY 2.65 million in the previous year, indicating a focus on innovation[16] Other Income and Subsidies - The company received government subsidies amounting to ¥7,108,985.58, a 236.77% increase compared to ¥2,110,950.00 in the previous year[8] - The company recorded other income of CNY 7.11 million, an increase from CNY 2.11 million in the same period last year[17] Borrowings - Short-term borrowings increased from CNY 202,639,026.75 to CNY 216,187,674.25, an increase of approximately 6.77%[13] - Long-term borrowings increased from CNY 408,459,555.56 to CNY 436,459,555.56, an increase of about 6.85%[13] - The company received 98,000,000.00 CNY in borrowings during the quarter, compared to 55,530,100.00 CNY in the previous year[20] Audit Status - The first quarter report was not audited[21]

Financial Performance - The company's operating revenue for 2023 was CNY 1,741,628,407.17, representing a 20.51% increase compared to CNY 1,445,239,989.37 in 2022[24]. - The net profit attributable to shareholders was a loss of CNY 332,260,445.98, a slight increase in loss of 3.61% from a loss of CNY 320,692,444.11 in the previous year[24]. - The net cash flow from operating activities was a negative CNY 383,302,095.05, a significant decline of 495.78% compared to a negative CNY 64,335,908.57 in 2022[24]. - The total assets at the end of 2023 reached CNY 3,399,589,930.03, marking a 130.40% increase from CNY 1,475,544,376.48 at the end of 2022[24]. - The net assets attributable to shareholders decreased by 92.95% to CNY 25,221,286.52 at the end of 2023, down from CNY 357,586,939.14 at the end of 2022[24]. - The basic earnings per share for 2023 was -CNY 0.8911, a decrease of 3.91% from -CNY 0.8576 in 2022[24]. - The company reported a net profit loss after deducting non-recurring gains and losses of CNY 361,297,556.68, which is a 40.93% increase in loss from CNY 256,369,957.31 in 2022[24]. - The company's operating revenue for 2023 was ¥1,741,628,407.17, an increase of 20.5% compared to ¥1,445,239,989.37 in 2022[26]. - The net profit attributable to shareholders for the fourth quarter was -¥196,285,715.17, with a total annual net profit of -¥352,260,546.98[30]. - The company's cash flow from operating activities for the fourth quarter was -¥268,567,195.42, indicating significant cash outflow[30]. Business Strategy and Development - The company has a focus on research and development of new products and technologies, although specific details were not provided in the documents[3]. - The company completed the acquisition of 51% of Anhui Xuhe Technology New Energy Co., Ltd. in October 2023, transitioning its main business to include both agricultural chemicals and photovoltaic new energy[24]. - The company has shifted its main business focus back to agricultural chemicals after divesting its pharmaceutical segment in 2020[24]. - The company plans to enhance production efficiency and product quality through continuous production process improvements and DCS automation control[38]. - The company aims to strengthen safety and environmental upgrades to improve capacity utilization[38]. - The company is focusing on R&D for new formulations and products to establish a comprehensive solution capability in the agricultural sector[38]. - The company plans to expand its market presence by leveraging its established reputation and early entry into the market for several key products[53]. - The company is exploring potential mergers and acquisitions to strengthen its market position, with a budget of 200 million yuan allocated for this purpose[55]. - The company is actively seeking to leverage the expertise of its newly appointed directors and managers to drive future growth initiatives[140]. Market Conditions and Risks - Future development outlook includes potential uncertainties and risks that investors should be aware of[4]. - The management emphasized the importance of risk awareness regarding market competition, safety and environmental risks, and raw material price fluctuations[4]. - The global agricultural market is currently in a destocking cycle, leading to cautious purchasing strategies among downstream distributors[38]. - The photovoltaic industry is experiencing cyclical risks due to changes in supply and demand relationships, impacting profitability[117]. - The company faces competition risks in the pesticide market due to numerous small manufacturers and increasing entry of international giants[114]. Research and Development - The company is investing 100 million yuan in R&D for innovative pesticide technologies, focusing on environmentally friendly solutions[54]. - The company is developing new technologies and products, including a continuous chemical process for surfactants and optimization of various production processes to enhance efficiency and reduce costs[82][83]. - The company has applied for over 50 patents during the reporting period, with 6 utility model patents granted[65]. - The company has a robust R&D system led by an expert advisory team, focusing on market-driven technology strategies and collaboration with academic institutions[61]. Corporate Governance - The company has a total of 8 board members, including 3 independent directors, ensuring a fair and transparent election process[123]. - The supervisory board consists of 3 members, with 1 employee representative and 2 non-employee representatives, and held 10 meetings during the reporting period[124]. - The company maintains complete independence in assets, personnel, finance, organization, and business from its controlling shareholders[127]. - The company has established an independent financial department with a dedicated accounting system, ensuring independent financial decision-making[128]. - The company held its annual general meeting on May 19, 2023, with a participation rate of 34.77%[130]. Environmental and Safety Compliance - The company has implemented significant environmental and safety measures, ensuring no major accidents occurred during the year[70]. - The company has adhered to environmental protection laws and standards, including the "Environmental Protection Law of the People's Republic of China"[178]. - The company has a wastewater treatment capacity of 3000 tons per day, with a chemical oxygen demand (COD) of 40.79 mg/L and ammonia nitrogen (NH3-N) of 2.039 mg/L, meeting the discharge standards set by the environmental authorities[182]. - The company has invested in 10 online monitoring devices for wastewater and air emissions to ensure real-time data transmission to environmental authorities[185]. - The company has established a hazardous waste storage facility with an area of 1584 m², capable of storing up to 2000 tons, complying with regulations that limit storage time to 90 days[184]. Employee Welfare and Development - The company has a commitment to employee welfare, ensuring full payment of social insurance and providing career development support for new employees[188]. - The company has implemented a detailed vocational training system, ensuring that all employees receive no less than 15 hours of training annually, significantly enhancing their work skills[189]. - The company has established a compensation management system to ensure internal fairness and external competitiveness in employee salaries[159]. Future Outlook - Future outlook includes a projected revenue growth of 10% for 2024, driven by new product launches and market expansion strategies[55]. - The company is expected to enhance its market expansion efforts in light of the new management appointments[134]. - The company has set a three-year shareholder return plan (2023-2025) aiming for a minimum return of 30%[155]. - The company is committed to sustainable practices, aiming to reduce operational costs by 10% through efficiency improvements in production processes[198].

证券代码：002513 证券简称：蓝丰生化 编号：2024-023 江苏蓝丰生物化工股份有限公司 关于公司涉及诉讼的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、案件所处的诉讼阶段：法院已受理，尚未开庭 2、上市公司所处的当事人地位：被告 3、涉案金额：23,971,243.10 元 4、对公司损益产生的影响：本次诉讼尚未开庭审理，对本期利润及期后利 润的影响尚不确定。敬请广大投资者关注公司在指定信息披露媒体上披露的相关 公告，理性投资，注意投资风险。 一、本次诉讼事项受理的基本情况 江苏蓝丰生物化工股份有限公司（以下简称"公司"或"蓝丰生化"）于近 日收到浙江省义乌市人民法院送达的案号为（2024）浙0782民初6684号《传票》 和《民事起诉状》等相关法律文书；江西省玉山县人民法院送达的案号为（2024） 赣1123民初1363号、（2024）赣1123民初1353号《传票》和《民事起诉状》等相 关法律文书，现将有关情况公告如下： 二、有关案件的基本情况 （一）浙江德施普诉蓝丰锦纶、江西德施普、蓝丰生化房屋租赁合同纠纷案 1、诉讼各 ...